Research Overview of Mepolizumab for the Treatment of Severe Eosinophilic Asthma
Mepolizumab,a humanized anti-interleukin-5 (IL-5) monoclonal antibody,is a biological agent,which shows a significant therapeutic prospect for a variety of inflammatory diseases caused by eosinophilia.In January 2024,China officially approved the new indication of mepolizumab for the treatment of severe eosinophilic asthma,further broadening its scope of clinical application.This article reviews the pharmacodynamics,pharmacokinetics,clinical efficacy,safety,usage and dosage of mepolizumab.
万方数据
维普
